Our Company
Our mission is to change the standard of care for patients with immunologic diseases. We are developing multiple novel biologic molecules toward this end.
Our lead clinical candidate is atacicept:
- A fusion protein that acts as an inhibitor of B cells and plasma cells, the cells that can produce disease causing antibodies.
- In a Ph2b clinical trial, the ORIGIN study, for IgA nephropathy (IgAN), an autoimmune disease that leads to kidney failure – for which no disease-modifying treatment is currently available.
- Initiating a Ph 3 clinical trial in Lupus Nephritis (LN), a severe kidney manifestation of systemic lupus erythematosus (SLE).
- Target profile: self-administered subcutaneously once per week.
We are also advancing MAU868:
- A monoclonal antibody that neutralizes infection by blocking BKV virion binding to host cells.
- In a Ph2 clinical trial for treatment of BK viremia in kidney transplant patients.
- No BK-specific treatment currently available.
- Target profile: monthly IV administration.